Survivin-targeted adoptive T-cell products have potent anti–acute myeloid leukemia activity, and other survivin-based vaccines, cellular therapies, and gene therapies have shown potent antitumor efficacy and favorable safety (71, 75, 76). This evidence concerns the gene BIRC5 and acute myeloid leukemia.